Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.
Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.
Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.
Radiotherapy may improve survival among men with low metastatic burden, but not in all patients with metastatic prostate cancer.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
The regimen did not improve survival and increased bone fractures.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.
Cancer occurrence in island Puerto Ricans and Puerto Ricans living in the continental US and Hawaii differ considerably.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Differences in TMB between African and European patients show that "racial mutational disparity is not a technical or computational artifact," according to authors.
Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.
Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.
A new white paper emphasizes the benefits of germline testing.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Recent analyses suggest that lifetime intake and early-life alcohol use may significantly contribute to the development of high-grade prostate cancer.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate CancerJuly 31, 2018
Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified